Introduction
Atrial natriuretic peptide (ANP) is secreted in response to atrial stretch and increases sodium excretion, inhibits the reninangiotensin-aldosterone, sympathetic activity and endothelin release. These vasoconstrictive neurohormonesdecrease renal blood flow, retain body fluid and aggravate heart failure.
Recently, studies using a novel natriuretic peptide receptor antagonist have demonstrated a role for endogenousreceptor ANPin cardiorenal homeostasis in normal and heart failure conditions (1) (2) (3) . The importance of ANP, however, in the regulation of hormonal and renal function in heart failure remains controversial. Our previous studies have shown that the vasodilatory effects of ANPappear to be attenuated in advanced heart failure, suggesting the down-regulation of ANP receptors in vascular beds (4) . Recent clinical studies have demonstrated that ANPinfusion to patients with heart failure is effective, although the response is less sensitive with regard to the renal, hormonal and hemodynamicchanges compared with normal control subjects (5-7). The objective of the current study was to establish the functional roles of endogenous ANPin regulating renal and neurohumoral function by investigating ANP suppression, endothelin and angiotensin II suppression in a canine model with heart failure. The effect of endogenous ANPin the setting of mild heart failure Weproduced a canine model of heart failure by rapid ventricular pacing. The rapid ventricular pacing model (at 240-270 beats per minute for 21 days) has been used extensively by our laboratory and by others to produce a model of severe heart failure. In the present study we adopted the pacing rate at 270 beats per minute for 10 days to produce a milder form of tachycardia-related cardiomyopathy. In this milder model of heart failure HS-142-1 produced decreases in renal CGMP generation, GFRand RPF, associated with decreases in urinary sodiumexcretion and fractional excretion of sodium. Fractional reabsorption of sodium at both the proximal and distal tubular levels increased. There was a significant increase in plasma renin activity associated with a trend toward an increase in plasmaaldosterone concentration.
The findings of the current study support a pathophysiological role for ANPin mediating renal homeostasis in evolving heart failure.
The effect ofendogenous ANPin the setting of severe heart failure EndogenousANPcontributes to renal homeostasis and the suppression of the activation of the renin-angiotensin-aldosterone system. However, in severe heart failure endogenous ANP secretion increases more than in mild heart failure, which is associated with a depressed level of CGMP production despite the elevated level ofANP. This may be due to the downregulation of guanylate cyclase-coupled ANPreceptors in vascular beds (9). HS-142-1 injection decreased urine volume and absolute sodiumexcretion, although there were no significant changes in GFR, RPF, or filtration fraction (FF). Therefore, endogenous ANPmay have actually contributed to the excretion of sodium and water in severe heart failure without causing significant changes in GFR or RPF. Although ANPinduces a preglomerular vasodilation and a post glomerular vasoconstriction with enhanced natriuresis in the normal hemodynamics, the vasodilative effect ofendogenous ANPon the afferent arteriole seemed to be diminished, since there was no significant change in FF in the heart failure.
HS-142-1 increased plasma renin activity and aldosterone and plasma norepinephrine levels (Fig. 1) . Therefore, endogenous ANPcounteracted the vasoconstrictive and antinatriuretic hormones in heart failure. Exogenous ANP, infused intravenously, reportedly suppresses renin secretion, however, whether endogenous ANP has an inhibitory effect on renin release remains controversial. Although ANP-mediated renin inhibi- Figure 1 . The effect of HS-142-1 on plasma renin activity, aldosterone and norepinephrine levels. HS-142-1 increased plasma renin activity, aldosterone and norepinephrine levels, indicating that endogenous ANPcounteracted the vasoconstrictive and antinatriuretic hormones in heart failure.
tion mayinvolve a macula densa mechanism,the results of the present study do not allow us to distinguishbetween this and a direct receptor-mediated mechanism. A very high density of ANPreceptor binding sites in the kidney was reported over the inner medulla, and the threshold ANPconcentration for an increase in CGMP accumulation in the inner medullary collecting duct has been reported to be about 100 times highr than that in the glomeruli (9).
The anti-heart failure effect of angiotensin II antagonist Angiotensin II increases glomerular efferent arteriolar tone and the filtration fraction, leading to increased solute reabsorption in the proximal tubule. In addition angiotensin II activates CGMPphosphodiesterase, resulting in the increased destruction of CGMP. Therefore, angiotensin II antagonist inhibits the action of phosphodiesterase, and elevates the action of ANP. We administered angiotensin II antagonist (TCV-1 16) to dogs with pacing-induced heart failure for 2 weeks and compared it with a vehicle group. There was no significant difference in the pulmonary capillary wedge pressure or the plasma ANPbetween the TCV-1 16 treated groups and the vehicle group. The plasma CGMP levels, a second messenger of ANP, were two times higher in TCV-1 16 treated groups than in the vehicle group (10). This study indicates that angiotensin II antagonist upregulates guanylatecyclase-coupled ANPreceptor in heart failure, resulting in the increased production of CGMP.
The antiheart failure effect of selective endothelin antagonist A recent report demonstrates that the endothelin concentration in the left ventricle in experimental heart failure was elevated and that ET-A receptor antagonist improves survival (1 1). ET-A receptors mediate vasoconstriction, while ET-B receptors mediate vasorelaxation via the release of nitric oxide and prostacyclin. However, ET-Breceptors also exist in smooth muscle and mediate vasoconstriction (12). Therefore, it may be valuable to see if both ET-Aand ET-Bantagonists are more effective whenadministered together rather than alone. We administered either ET-Areceptor antagonist or ET-Breceptor antagonist to dogs with heart failure induced by rapid ventricular pacing. The effects of both antagonists on hemodynamic, hormonal, and renal functions were studied. ET-A antagonist decreased cardiac pressures and the plasma ANPlevel and increased cardiac output. Urine flow rate and urinary sodium excretion were increased accompanied by an increase in both Progression of heart failure Figure 2 . The relation between neurohumoral factors and the mechanism of body fluid retention in heart failure. Administration of various antagonist for each neurohumoral factor discloses the contribution of ANP, BNP, renin, angiotensin II, aldosterone and endothelin to modulating the sodium-water balance through cardiac and renal hemodynamics in heart failure.
Internal Medicine Vol. 37, No. 2 (February 1998) presses the releases of renin, angiotensin II, aldosterone, and endothelin ( Fig. 2) . Angiotensin II antagonist prevents the progression of heart failure by improving renal function. One of the mechanisms for the improvement of renal function is due to the up-regulation of ANPreceptor, which leads to an increase in the production of CGMP at a given ANPconcentration. ET-A antagonist has potential therapeutic benefits not only related to cardiac hemodynamics but also to renal sodiumwater regulation. ET-B antagonist possesses favorable effects of the suppression of the renin-angiotensin-aldosterone system in the treatment of heart failure.
